In this phase I study, 49 patients with previously treated advanced KRAS G12C mutated CRC, without prior KRAS G12C inhibition, were given LY3537982 100 mg or 150 mg twice daily with cetuximab. The gene discussed is KRAS; the disease is colorectal carcinoma.